Why is the ResApp share price crashing 29% today?

ResApp shares have been hammered on Tuesday…

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResApp shares have returned from their trading halt and crashed deep into the red
  • This morning the company revealed disappointing study results for its COVID-19 algorithm
  • This has reduced the takeover offer from Pfizer Australia

The ResApp Health Ltd (ASX: RAP) share price has returned from its trading halt and taken a tumble.

In morning trade, the digital health company's shares are down 29% to 12.5 cents.

Why is the ResApp share price crashing?

Last week, as we reported here, ResApp received an improved takeover offer from pharmaceutical giant Pfizer Australia.

Originally, Pfizer Australia was offering to acquire the company for 11.5 cents per share in cash. However, this fell short of the independent expert's valuation of 14.6 cents to 27.7 cents, with a preferred value of 20.7 cents per share.

In response to this, Pfizer agreed to increase its offer to either 14.6 cents or 20.7 cents per share.

The ultimate price would depend on the results of a clinical validation study of ResApp's COVID-19 algorithm. If the study was close to matching the results of its previous study, Pfizer would pay 20.7 cents per share. If the results fell short of the previous study, Pfizer would pay 14.6 cents per share.

What's the latest?

As you might have guessed from the ResApp share price performance today, the clinical validation study wasn't overly successful.

According to the release, the data confirmation study showed that ResApp's COVID-19 algorithm achieved a sensitivity of 84% and a specificity of 58%. This is significantly lower than the results of ResApp's pilot study and falls short of the minimum sensitivity of 86% and a minimum specificity of 71%.

These results were both calculated by ResApp and independently analysed and verified by a highly qualified and respected independent third-party statistician.

ResApp's CEO and Managing Director, Tony Keating, appeared disappointed with the study but remains positive on the future. He said:

While we remain confident that our algorithms can detect COVID-19 using cough sounds, they will require further refinement, testing and validation to ensure that they perform to the level needed. This work will continue with the benefit of now having over 1,300 additional cough sound recordings with gold standard PCR test results to use to train and improve the algorithms. Notwithstanding, the results underscore the considerable work, challenge and cost of bringing our technology to market.

What now?

As the confirmatory data readout condition under the revised scheme was not satisfied, the scheme consideration will be 14.6 cents per share in cash. This represents an equity value of $127 million.

The ResApp board continues to recommend that shareholders vote in favour of the offer. That's if the deal still goes ahead. They will no doubt be hoping Pfizer doesn't pull the plug on the deal following this disappointing study.

Should you invest $1,000 in Resapp Health right now?

Before you buy Resapp Health shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resapp Health wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Mergers & Acquisitions

Man pointing at a blue rising share price graph.
Mergers & Acquisitions

Guess which ASX All Ords tech stock just rocketed 30% on takeover news

The ASX All Ords tech stock is bucking the broader tech sell-off today to rocket higher.

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Mergers & Acquisitions

Fortescue shares slide on $254m Pilbara acquisition

This mining giant is making a new acquisition. Here's what it has announced.

Read more »

Mergers & Acquisitions

Myer shares race higher on 'overwhelming support' for merger

The department store expects the merger to create a stronger business.

Read more »

Multiple ASX share investors take on one another in a tug of war in a high rise building.
Mergers & Acquisitions

Insignia Financial shares: When will the bidding war end?

Bidding action for the ASX 200 financial stock continues today.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Mergers & Acquisitions

How Rio Tinto shares could eclipse BHP in 2025, with a little help from Glencore

The financial rumour mill is abuzz about a potential mega merger for Rio Tinto.

Read more »

A man wearing a shirt, tie and hard hat sits in an office and marks dates in his diary.
Materials Shares

BHP share price higher on US$2b acquisition to support artificial intelligence market

BHP is ready to step up and help support the booming AI megatrend.

Read more »

A woman in a business suit and a man in a business suit boxing in a ring.
Financial Shares

ASX 200 financial stock races higher amid takeover bidding war

This stock has received competing takeover bids this month.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Materials Shares

Why this $10 billion ASX lithium stock is surging 8% today

This lithium miner is making its shareholders smile on Thursday. But why?

Read more »